Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis. Dermatol Reports [Internet]. 2022 Mar. 17 [cited 2025 Jun. 19];14(3). Available from: https://journals.pagepress.org/dr/article/view/9282